Multiplex Assay Kit for Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay)

PLAU; ATF; URK; UK; UP-A; Abbokinase; Urokinase-Type Plasminogen Activator

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 86-93 90
EDTA plasma(n=5) 80-101 96
heparin plasma(n=5) 96-104 99

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 80-94% 98-105% 91-99% 82-98%
EDTA plasma(n=5) 96-103% 84-99% 99-105% 78-94%
heparin plasma(n=5) 92-101% 92-101% 86-104% 84-91%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:uPA) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Breast Cancer Research and Treatment Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice SpringerLink: f3w831267267p277
Biomarker insights Decreased Hepatocyte Growth Factor (HGF) and Gamma Aminobutyric Acid (GABA) in Individuals with Obsessive-Compulsive Disorder (OCD) PubMed: PMC3762604
Oncol Rep. Downregulation of MACC1 inhibits invasion, migration and proliferation, attenuates cisplatin resistance and induces apoptosis in tongue squamous cell carcinoma Pubmed:25421538
International Journal of Oncology 1, 25-Dihydroxyvitamin D3 alleviates salivary adenoid cystic carcinoma progression by suppressing GPX1 expression through the NF-κB pathway Pubmed:26782341
Biochemical and Biophysical Research Communications Methylation of neurofilament light polypeptide promoter is associated with cell invasion and metastasis in NSCLC Pubmed:26801564
39 Cytokine and Estrogen Stimulation of Endothelial Cells Augments Activation of the Surface-Bound Prekallikrein-High Molecular Weight Kininogen Complex: Implications for Hereditary Angioedema (HAE): 814 article:S0091-6749(15)02643-3
SCIENCE & TECHNOLOGY A Study Protocol: Spinal Morphology, Physical Performance, Quality of Life and Biochemical Markers in Adults at Risk of Osteoporotic Fractures 59f7c85aaca272607e2d8d7a
Oncotarget Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma pubmed:28404945
Journal of allergy and clinical immunology Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema. pubmed:27826093
Molecular Medicine Reports Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro Pubmed:29328476
Phytomedicine Multi-omics analysis reveals the mechanisms of action and therapeutic regimens of traditional Chinese medicine, Bufei Jianpi granules: Implication for COPD drug … Pubmed:35121390
Cellular and Molecular Life Sciences IL4 stimulated macrophages promote axon regeneration after peripheral nerve injury by secreting uPA to stimulate uPAR upregulated in injured axons Pubmed:35536429
Catalog No. Related products for research use of Bos taurus; Bovine (Cattle) Organism species Applications (RESEARCH USE ONLY!)
RPA140Bo01 Recombinant Plasminogen Activator, Urokinase (uPA) Positive Control; Immunogen; SDS-PAGE; WB.
PAA140Bo01 Polyclonal Antibody to Plasminogen Activator, Urokinase (uPA) WB; IHC; ICC; IP.
MAA140Bo21 Monoclonal Antibody to Plasminogen Activator, Urokinase (uPA) WB; IHC; ICC; IP.
MAA140Bo23 Monoclonal Antibody to Plasminogen Activator, Urokinase (uPA) WB; IHC; ICC; IP.
MAA140Bo22 Monoclonal Antibody to Plasminogen Activator, Urokinase (uPA) WB; IHC; ICC; IP.
SEA140Bo ELISA Kit for Plasminogen Activator, Urokinase (uPA) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA140Bo Multiplex Assay Kit for Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.